Savara (SVRA) Assets Average (2011 - 2026)
Savara (SVRA) posted quarterly Assets Average of $237.5 million for Q1 2026, up 18.12% year-over-year from $201.1 million in Q1 2025, and up 20.47% quarter-over-quarter from $197.2 million in Q4 2025.
Savara (SVRA) Assets Average (2011 - 2026) Analysis & Trends
Savara (SVRA) has reported Assets Average for 16 consecutive years, with $237.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 18.12% year-over-year to $237.5 million; the TTM figure through Mar 2026 stood at $237.5 million (up 18.12% YoY), while the FY2025 annual figure was $233.2 million, up 19.43% from the prior year.
- Assets Average grew to $237.5 million in Q1 2026 per SVRA's latest filing, from $197.2 million in the prior quarter.
- Across five years, Assets Average topped out at $237.5 million in Q1 2026 and bottomed at $124.6 million in Q2 2023.
- Historically, Assets Average has averaged $171.5 million across 5 years, with a median of $167.9 million in 2024.
- Annual changes were most pronounced in 2023 — Assets Average dropped 22.85% — and 2024, when it climbed 25.6%.
- Savara's Assets Average stood at $143.8 million in 2022, then advanced by 25.08% to $179.8 million in 2023, then grew by 25.6% to $225.8 million in 2024, then fell by 12.69% to $197.2 million in 2025, then advanced by 20.47% to $237.5 million in 2026.
- Business Quant data shows SVRA's Assets Average at $237.5 million in Q1 2026, $197.2 million in Q4 2025, and $152.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | 206.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 206.89 Mn |
| Mar 31, 2026 | 237.54 Mn |
| Dec 31, 2025 | 197.18 Mn |
| Sep 30, 2025 | 152.34 Mn |
| Jun 30, 2025 | 176.54 Mn |
| Mar 31, 2025 | 201.10 Mn |
| Dec 31, 2024 | 225.85 Mn |
| Sep 30, 2024 | 189.24 Mn |
| Jun 30, 2024 | 148.98 Mn |
| Mar 31, 2024 | 167.93 Mn |
| Dec 31, 2023 | 179.82 Mn |
| Sep 30, 2023 | 150.95 Mn |
| Jun 30, 2023 | 124.60 Mn |
| Mar 31, 2023 | 134.57 Mn |
| Dec 31, 2022 | 143.77 Mn |
| Sep 30, 2022 | 152.27 Mn |
| Jun 30, 2022 | 161.49 Mn |
| Mar 31, 2022 | 171.40 Mn |
| Dec 31, 2021 | 181.94 Mn |
| Sep 30, 2021 | 191.85 Mn |